CT REMEDClinical Trial REMED COVID-19 is still a significant challenge for medical research, exploring new drugs or possible optimizing the use of existing drugs. One way to use an existing medicine is to use the corticosteroid dexamethasone. REMED clinical trial aims to test the hypothesis that administration of dexamethasone 20 mg daily is more effective…
Read more

CT HALFClinical Trial HALF Masaryk University is the sponsor of a multicenter prospective phase II clinical trial called HALF, which evaluates the efficacy and safety of thyrosine kinase withdrawal nationwide after a previous two-stage dose reduction in patients with chronic myeloid leukemia in deep molecular remission. This 5-year clinical trial will take place in 8…
Read more

CZECRIN_4 PACIENTYCZECRIN_4 PACIENTY - bringing innovative advanced therapies The main research goal of the project is the development, manufacture and... Realisation period: 1. 7. 2017 - 30. 6. 2021 Registration number: CZ.02.1.01/0.0/0.0/16_013/0001826 Project title: CZECRIN_4 PACIENTY - bringing innovative advanced therapies Beneficiary: St. Anne's University Hospital in Brno Partners: Masaryk University Financed by programme: (OP…
Read more

FlyCellix™FlyCellix™ FlyCellix™ is a medicinal product consisting of allogeneic mesenchymal... FlyCellix™ is a medicinal product consisting of allogeneic mesenchymal stromal cells derived from adipose tissue. Allogeneic Adipose Tissue-derived Mesenchymal Stromal Cells is developed in CZECRIN - ACIU MUNI for patients with Epidermolysis Bullosa, rare disease with unmet medical need. CZECRIN - ACIU MU developed and…
Read more

[18F] -fluorocholin[18F] -fluorocholin Radiopharmaceutical, a medicinal product intended for PET/CT scan examination and diagnosis n early stages of prostatic cancer. Clinical trial [18F] -fluorocholin inj was initiated by CZECRIN in cooperation with Masaryk Memorial Cancer Institute (MMCI) Phase I Unit and currently is the product submitted and waiting for registration in Czech Republic. Nejdůležitější odkazy…
Read more

MyDendrix™MyDendrix™ Dendritic cells vaccine in children and young patients with progressive... Dendritic cells vaccine in children and young patients with progressive, recurrent or primarily metastatic high-risk tumors. Vaccine is developed and produced by the CZECRIN GMP Unit ACIU MU, and currently covered by insurance in line with the indication. Nejdůležitější odkazy Pro média Materiály ke…
Read more